Results 131 to 140 of about 1,848 (184)
Some of the next articles are maybe not open access.
Selexipag for the treatment of pulmonary arterial hypertension
American Journal of Health-System Pharmacy, 2017The pharmacology, pharmacokinetics, clinical efficacy, safety and tolerability, dosing and administration, and place in therapy of selexipag, an orally administered selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH), are reviewed.The first-in-class oral prostacyclin IP receptor agonist selexipag (Uptravi,
Zachary R Noel, Kazuhiko Kido
exaly +3 more sources
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
Annals of Pharmacotherapy, 2017 Objective: To evaluate the data supporting the approval of selexipag and discuss its potential place in therapy for managing pulmonary arterial hypertension (PAH).
exaly +2 more sources
Selexipag: First Global Approval
Drugs, 2016Selexipag (Uptravi(®)) is a highly selective, long-acting, nonprostanoid, prostacyclin receptor agonist that is being developed by Actelion Pharmaceuticals Ltd and Nippon Shinyaku. Oral selexipag is approved in the USA for the treatment of pulmonary arterial hypertension (PAH; WHO Group I) to delay disease progression and reduce the risk of ...
openaire +2 more sources